文献速递核素与放射性配体治疗放射性药物与辐射防护

抗体-放射性核素偶联物177Lu-利洛妥单抗司替曲坦治疗1期试验的生物分布与剂量学结果

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
PubMed 文献 · J Nucl Med · 2017-08-28

该1期试验纳入7例复发CD37阳性惰性非霍奇金淋巴瘤患者,使用177Lu-利洛妥单抗司替曲坦治疗,按两种预给药方案分组并接受10、15、20 MBq/kg不同活度水平,所有患者均预先接受利妥昔单抗。生物分布显示除红骨髓和肿瘤外,肝脏、脾脏和肾脏有明显摄取,脾脏剂量最高(1.54-3.60 mGy/MBq),两种预给药方案间软组织吸收剂量无统计学显著差异。

要点

  • 除红骨髓和肿瘤外,肝脏、脾脏和肾脏为明显摄取器官,脾脏剂量最高。
  • 脾脏剂量1.54-3.60 mGy/MBq,肝脏0.70-1.15 mGy/MBq,肾脏0.16-0.79 mGy/MBq。
  • 两种预给药方案间软组织吸收剂量无统计学显著差异。

核心结论

  • 177Lu-利洛妥单抗司替曲坦的生物分布研究显示,除红骨髓外,肝脏和脾脏的生理性摄取最高。
  • 在所有研究的治疗水平下,吸收剂量与常用耐受限值相比均较温和。

研究设计与样本

  • 1期/2a期首次人体剂量递增试验,纳入7例复发CD37阳性惰性非霍奇金淋巴瘤患者进行剂量学研究。

主要发现

  • 除红骨髓和肿瘤外,肝脏、脾脏和肾脏有明显摄取,脾脏摄取最高。
  • 脾脏剂量范围为1.54-3.60 mGy/MBq。
  • 肝脏剂量范围为0.70-1.15 mGy/MBq。
  • 肾脏剂量为所研究源器官中最低,范围0.16-0.79 mGy/MBq。
  • 全身剂量范围为0.08-0.17 mGy/MBq。

关键数值与推荐

  • 患者按两种预给药方案分组(联合或不联合40 mg利洛单抗预给药)。
  • 患者接受10、15、20 MBq/kg不同活度水平治疗。
  • 所有患者均预先接受利妥昔单抗治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-lilotomab satetraxetan is a novel antibody-radionuclide conjugate currently in a phase 1/2a first-in-humans dose escalation trial for patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. The aim of this study was to investigate biodistribution and absorbed doses to organs at risk. Methods: In total, 7 patients treated with 177Lu-lilotomab satetraxetan were included for dosimetry. Patients were grouped on the basis of 2 different predosing regimens (with and without predosing with 40 mg of lilotomab) and were treated with different levels of activity per body weight (10, 15, and 20 MBq/kg). All patients were pretreated with rituximab. Serial planar and SPECT/CT images were used to determine time-activity curves and patient-specific masses for organs with 177Lu-lilotomab satetraxetan uptake. Doses were calculated with OLINDA/EXM. Results: The organs (other than red bone marrow and tumors) with distinct uptake of 177Lu-lilotomab satetraxetan were the liver, spleen, and kidneys. The highest uptake was found in the spleen, with doses ranging from 1.54 to 3.60 mGy/MBq. The liver received 0.70-1.15 mGy/MBq. The kidneys received the lowest dose of the source organs investigated, 0.16-0.79 mGy/MBq. No statistically significant differences in soft-tissue absorbed doses were found between the two predosing regimens. The whole-body dose ranged from 0.08 to 0.17 mGy/MBq. Conclusion: The biodistribution study for patients treated with 177Lu-lilotomab satetraxetan revealed the highest physiologic uptake to be in the liver and spleen (besides the red marrow). For all treatment levels investigated, the absorbed doses were found to be modest when compared with commonly assumed tolerance limits.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Blakkisrud J, Holtedahl JE, Løndalen A, et al. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan. J Nucl Med. 2017. PMID: 28848035. doi:10.2967/jnumed.117.195347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。